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Abstract.  The tissue localization or "homing" of cir- 
culating lymphocytes is directed in part by specialized 
vessels that define sites  of lymphocyte exit from the 
blood. In peripheral lymph nodes, mucosal lymphoid 
tissues (Peyer's patches and appendix), and sites of 
chronic inflammation, for example, lymphocytes leave 
the blood by adhering to and migrating between those 
endothelial cells lining postcapillary high endothelial 
venules (HEV). Functional analyses of lymphocyte in- 
teractions with HEV have shown the lymphocytes can 
discriminate between HEV in different tissues, indicat- 
ing that HEV express tissue-specific determinants or 
address signals for lymphocyte recognition. We re- 
cently described such a tissue-specific "vascular ad- 
dressin" that is selectively expressed by endothelial 
cells supporting lymphocyte extravasation into mucosal 
tissues and that appears to be required for mucosa- 
specific lymphocyte homing (Streeter, P. R.,  E.  L. 
Berg, B.  N.  Rouse, R.  E  Bargatze, and E. C.  Butcher. 
1988. Nature (Lond.).  331:41-46).  Here we document 
the existence and tissue-specific distribution of a dis- 
tinct HEV differentiation antigen. Defined by monoclo- 
nal antibody MECA-79,  this antigen is expressed at 
high levels on the lumenal surface and in the 
cytoplasm of HEV in peripheral lymph nodes. By con- 
trast, although MECA-79  stains  many HEV in the 
mucosal Peyer's patches, expression in most cases is 
restricted to the perivascular or ablumenal aspect of 
these venules. In the small intestine lamina propria, a 
mucosa-associated site that supports the extravasation 
of lymphocytes, venules do not stain with MECA-79. 
Finally, we demonstrate that MECA-79 blocks binding 
of both normal lymphocytes and a peripheral lymph 
node-specific lymphoma to peripheral lymph node HEV 
in vitro and that it also inhibits normal lymphocyte 
homing to peripheral lymph nodes in vivo without 
significantly influencing lymphocyte interactions with 
Peyer's patch HEV in vitro or in vivo.  Thus, MECA- 
79 defines a novel vascular addressin involved in 
directing lymphocyte homing to peripheral lymph 
nodes. 
T 
ISSUE- or site-specific cell-cell interactions are thought 
to be important  in a variety of biologic  systems, in- 
cluding the targetting of neuronal processes,  the mi- 
gration of cells during morphogenesis, and the trafficking or 
"homing" of lymphocytes to specific tissues or organs in the 
body. The latter system has proven particularly accessible to 
experimental analysis, due to the availability of in vitro and 
in vivo assays of lymphocyte interactions with venules that 
support and direct the extravasation of lymphocytes from the 
blood into lymphoid tissues and sites of chronic inflamma- 
tion. In peripheral lymph nodes and mucosal lymphoid tis- 
sues (Peyer's patches and appendix),  lymphocytes leave the 
blood by adhering to and migrating between the morphologi- 
cally distinct  endothelium lining high endothelial  venules 
(HEV~; Gowans and Knight,  1964; Marchesi and Gowans, 
1. Abbreviations used in thispaper: HEC, high endothelial cells; HEV, high 
endothelial venules. 
1964). Lymphocyte entry into distinct lymphoid tissues can 
exhibit  remarkable tissue  specificity  (Guy-Grand  et  al., 
1974; Cahill et al.,  1977; McWilliams et al., 1977; Rose et 
al., 1978; Hall et al.,  1979; Chin and Hay, 1980; Smith et 
al.,  1980; Butcher,  1986), determined at least  in part by 
selective  recognition  of endothelial  cells  (Butcher  et al., 
1980; Chin et al., 1984; Jalkanen et al., 1986b; Schmitz et 
al., 1988). Functional in vitro studies have revealed the exis- 
tence of several independent lymphocyte high endothelial 
cell (HEC) recognition systems mediating lymphocyte entry 
into peripheral lymph nodes, mucosal lymphoid tissues, and 
into the synovium of inflamed joints (Butcher et al.,  1980; 
Jalkanen et al.,  1986b). Lymphocyte surface molecules in- 
volved in lymphocyte-HEC interactions have been defined 
(Gallatin et al., 1983; Rasmussen et al.,  1985; Chin et al., 
1986; Jalkanen et al., 1986a; Jalkanen et al., 1987; Hamman 
et al., 1988; Pals et al., 1988; Wu and Butcher, manuscript 
in  preparation);  those  that appear to  mediate tlssue-spe- 
©  The Rockefeller  University Press, 0021-9525/88/11/1853/10 $2.00 
The Journal of Cell Biology, Volume 107, November 1988  1853-1862  1853 cific endothelial cell recognition have been termed "homing 
receptors". 
In an effort to identify endothelial cell surface antigens that 
function as tissue-specific position markers or address sig- 
nals  for recognition by circulating lymphocytes, we pro- 
duced mAbs  against mouse  HEC.  We  have  recently de- 
scribed  one  such  "vascular addressin" that  is  selectively 
expressed in mucosal tissues and appears to be required for 
lymphocyte extravasation  into  mucosal  lymphoid organs 
(Streeter et al.,  1988).  Here we describe the existence and 
patterns of expression of an antigenically distinct vascular 
addressin that is involved in lymphocyte  trafficking into non- 
mucosal peripheral lymph nodes. Like its functional coun- 
terpart in mucosal lymphoid tissues, this addressin is ex- 
pressed in a tissue-selective manner. The mAb raised against 
this peripheral  lymph node addressin blocks  the  in  vitro 
binding of lymphocytes to peripheral lymph node HEV, and 
inhibits the  homing of lymphocytes to  peripheral  lymph 
nodes in vivo. 
Materials and Methods 
mAb Production 
Antigen isolation/preparation: axillary,  brachial, inguinal, and mesenteric 
lymph nodes from 8-12-wk-old BALB/c mice (Institute for Medical Re- 
search, San Jose, CA) were pooled in Hanks' balanced salt solution (HBSS), 
minced, and gently pressed between glass microscope slides to release lym- 
phocytes. The resulting cell suspension was then passed through nitex nylon 
mesh (Sullivan Co., San Francisco, CA). The stromal elements that remained 
on top of the mesh were collected, treated for 10 min at 37°C with HBSS 
containing 0.32 mg collagenase/ml (5 ml/mouse), washed, and again passed 
through nitex. The stromal elements remaining on the nitex were collected, 
suspended in HBSS, and used for immunizations. 
Immunization and bybridoma production: a Wistar rat (Simonsen Labo- 
ratories,  Inc.,  Gilroy,  CA)  was  immunized  with  collagenase-dispersed 
stromal elements mixed with precipitated aluminum potassium sulfate (ad- 
juvant/carrier) in a 3:2 ratio, final volume 1 ml, and delivered i.p. 4 d before 
fusion, the rat was boosted i.p. with stromal cells (from 10 mice) in HBSS. 
Spleen cells from immune animals were fused (Kohler and Milstein, 1975) 
with the mouse myeloma Sp2/0 (Schulman et al., 1978), and hybrids were 
selected in medium containing hypoxanthine, aminopterin, and thymidine. 
Supernatants from hybrid-containing wells were initially screened on tissue 
sections by immunofluorescence. The MECA-79  secreting hybridoma was 
subcloned three times by limiting dilution, and adapted to serum free HB101 
medium (New England Nuclear, Boston, MA). The isotype of MECA-79 
was determined to be IgM by Ouchterlony analysis. 
Rat IgM control mAbs included 2C2, an antibody defining a B cell lin- 
eage antigen, B220 (Coffman and Weissman, 1981), a gift from R. Coffman 
(DNAX Research Institute, Palo Alto, CA); and OZ-42, an antibody that 
binds a determinant expressed in developing mouse brain, generously sup- 
plied by L. Pickford and R. Rouse. 
Additional mAbs used in this investigation included MECA-367, a rat 
IgG2a that defines a vascular addressin in mucosal lymphoid tissues of the 
mouse  (Streeter  et  al.,  1988),  and  a  class-matched control  antibody, 
Hermes-l, that binds lymphocyte homing receptors in man but does not re- 
act with mouse tissues (Jalkanen et al.,  1986a). 
Immunofluorescence Staining 
One-color immunofluorescence: supernatants from hybrid-containing wells 
were initially screened for reactivity with tissue-specific markers on mouse 
HEV by immunofluorescence staining of acetone fixed frozen sections con- 
taining both peripheral lymph nodes and Peyer's patches. Briefly,  sections 
were  incubated  with  culture  supernatants,  washed,  and  exposed  to  a 
fluoresceinated goat anti-rat  Ig  (Sigma Chemical Co.,  St.  Louis,  MO) 
diluted 1:40 in PBS containing 5% normal mouse serum. 
Two-color  immunofluorescence:  two  color  visualization  of  distinct 
markers on endothelial cells was accomplished by using a three-stage detec- 
tion system for rat IgM, and a two-stage detection system for rat IgG. Briefly, 
after incubation with either experimental (MECA-79  and MECA-367), or 
class-matched control  antibodies  (OZ-42  and  Hermes-l),  sections  (or 
enzyme-dispersed  endothelial cells, see below) were washed and incubated 
in an affinity-isolated biotinylated goat anti-rat IgM (Kirkegaard &  Perry 
Laboratories, Inc., Gaithersburg, MD; diluted 1:80) in PBS containing 5% 
normal mouse serum. The sections (or enzyme-dispersed  endothelial cells) 
were then washed, and incubated with PBS containing texas red conjugated 
avidin (Cappel Laboratories,  Malvern, PA; diluted 1:50), an affinity-isolated 
fluoresceinated goat antibody to rat IgG (Kirkgaard and Perry Laboratories, 
Inc.; diluted 1:80),  a rat monoclonal IgM (either OZ-42 or MECA-79)  at 
a concentration of 100 p.g/ml (to block low level reactivity of the anti-rat 
IgG with section bound rat IgM), and 5%  NMS. 
Immunoperoxidase Staining 
Immunoperoxidase staining of acetone fixed frozen sections of lymphoid 
and  extralympboid tissues  was  performed using  a  standard  technique. 
Briefly,  sections were incubated with purified mAb in PBS, washed, and 
treated with a solution of PBS containing a 1:40 dilution of horseradish per- 
oxidase-conjugated rabbit anti-rat IgG (DAKOPATTS,  Copenhagen; this 
reagent  reacts  with  rat  IgM)  and  5%  NMS.  The  horseradish  peroxi- 
dase-conjugated second antibody was detected after exposure to a solution 
of 0.05M  Tris (pH 7.6) containing 0.05%  diaminobenzidine and 0.009% 
H202 (wt/vol), and the staining was enhanced by incubation in 0.5% cop- 
per sulfate in saline. Hematoxylin was used to lightly counterstain sections. 
Slight modification of the procedure described above allowed detection 
of either rat IgM or rat IgG after the intravenous administration of a mixture 
containing both antibodies. Briefly,  IgM was detected using a three-stage 
system, with an affinity isolated biotinylated second stage goat antibody to 
rat IgM (Kirkegaard & Perry Laboratories, Inc.; diluted 1:80 in PBS con- 
raining 5% NMS), and horseradish peroxidase-labeled streptavidin as the 
third stage (Kirkegaard & Perry Laboratories, Inc.; diluted 1:80 in PBS). 
IgG was detected using an affinity-isolated horseradish peroxidase-labeled 
goat anti-rat IgG (Kirkegaard &  Perry Laboratories, Inc.) diluted l:10 in 
PBS  containing 5%  NMS and a  rat  monoclonai IgM  (either OZ-42 or 
MECA-79) at a concentration of 100 p.g/ml (to block reactivity with rat IgM 
on the section). The horseradish peroxidase-conjugated reagents were de- 
tected as described above. 
Cells 
Normal lymphocytes: mesenteric lymph nodes from 6-12-wk-old BALB/c 
mice were minced in HBSS and gently pressed between glass microscope 
slides to release lymphocytes. The cell suspension was then passed through 
nitex to eliminate stromal elements. The lymphoid cells were then washed 
(2 x) in HBSS, and used in either in vitro lymphocyte-HEV binding assays, 
or in vivo homing experiments. 
Lymphomas:  we  used  two  well-characterized lympbomas,  TK1  and 
38C13 (Butcher et al., 1980; Gallatin et al., 1983), for in vitro HEV binding 
assays. TK1, stored frozen in liquid nitrogen and used here immediately af- 
ter thawing, specifically binds HEV in mucosa-associated tissues (Butcher 
et al.,  1980).  The lymphoma 38C13,  which for these studies was taken 
directly from an adoptive recipient of  the tumor, binds HEV via an alternate, 
peripheral lymph node-specific recognition system (Gallatin et al., 1983). 
Endothelial cells: viable HEC, in single cell suspension, were prepared 
using a modification of an enzyme-dispersion protocol provided by E  An- 
drews. Briefly,  mesenteric lymph node stromal elements (isolated as de- 
scribed above) were treated for 30 min (37°C) with HBSS containing 0.32 
mg of collagenase per ml (5 ml per mouse). Stromal elements were allowed 
to sediment at  1 g  for 10 min, and the supernatant was decanted. After 
repeating this enzymatic treatment/sedimentation procedure (lx), stromal 
elements were treated for 30 min (37°C) with HBSS containing 0.32 mg of 
collagenase and 0.4 mg of dispase per ml (5 ml per mouse). After washing 
the enzyme-dispersed cells (2x) with HBSS containing 5% newborn calf 
serum, cells were either stained in suspension for two-color immunofluores- 
cence analysis (as described above), or were used to prepare cytospins that 
were then acetone fixed (permeabilized) and stained. For cytospins, cells 
from 5 mice were resuspended in 2 ml of HBSS/5% NCS, and 200 I.tl ali- 
quots were spun for 5 rain at  1,000 rpm. 
In Vitro  Lymphocyte-HEV  Binding  Assay 
The in vitro assay of lymphocyte  binding to HEV in frozen sections has been 
described (Stamper and Woodruff,  1976; Butcher et al.,  1979),  but was 
modified  slightly  for  these  studies.  Briefly,  12-1xm-thick,  freshly  cut, 
unfixed tissue sections (Peyer's patches, mesenteric lymph nodes, and pe- 
ripheral lymph nodes), were pretreated for 30 min at 7°C with 100 t.tl of 
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a concentration of 100 txg/ml in RPMI 1640 medium containing 5% new- 
born calf serum and 20 mM Hepes, pH 7.2 (complete medium), or complete 
medium alone.  After pretreatment,  medium was removed from both ex- 
perimental and control  sections, and 5  x  105-3  x  106 lymphocytes or 
lymphoma cells were applied in 100 ~tl of complete medium. After mild 
rotation for 30 min at 7°C, nonadherent cells were decanted, and adherent 
cells were fixed to tissue sections by emersion in cold PBS containing 1.5% 
glutaraldehyde. Cell binding to HEV was assessed microscopically under 
darldield illumination, and the mean number of bound cells per HEV was 
determined.  Results are presented as percent of media control (+SEM). 
In Vivo  Lymphocyte  Homing Assay 
In vitro labeling of lymphocytes with 5~Cr: normal mesenteric lymph node 
cells from 6-10-wk-old BALB/c mice were labeled with 5~Cr as previously 
described (Streeter et al., 1988). Briefly, lymphocytes were labeled by incu- 
bation of 2.5  x  107 cells/ml for 1.5 h at 37°C, with mixing every 15 min, 
in DME supplemented with 20 mM Hepes, 5% FCS, and 100 lxCi/ml so- 
dium chromate (Na251CrO4; New  England Nuclear).  After labeling, the 
cells were centrifuged through a layer of FCS, and washed twice with HBSS. 
In vivo homing: recipient syngeneic mice were injected intravenously 
with 1 mg of either MECA-79 or control monoclonal IgM antibody OZ-42 
diluted in HBSS. After 4  h, 2.5  ×  107 chromium-labeled cells were ad- 
ministered intravenously. 2 h later, animals were sacrificed, and lymphocyte 
localization was determined by quantitating the cpm in the indicated organs. 
Results are presented as percent of isotype matched control (+SEM). 
Results 
Production of  MECA-79 
Collagenase-dispersed  mesenteric  and  peripheral  lymph 
node stromal  elements were  used as  immunogen for the 
production of mAbs defining tissue-specific endothelial cell 
molecules involved in lymphocyte homing. Initial screening 
of hybridoma supernatants by inununofluorescence revealed 
one well containing antibody (MECA-79)  that selectively 
stained peripheral lymph node HEV. 
Expression Patterns of the MECA-79  Antigen 
Immunohistologic examination of frozen sections revealed 
that  MECA-79  stained  all  HEV  in  peripheral  (axillary, 
brachial, and inguinal) lymph nodes with intense cytoplas- 
mic as well as apparent lumenal and ablumenal cell surface 
reactivity (Fig.  1 a).  In contrast, HEV in mucosal Peyer's 
patches  of the  small  intestine exhibited variable  staining. 
While a subset of Peyer's patch HEV was completely nega- 
tive, most of the HEV in this tissue stained with MECA-79. 
However, unlike the staining in peripheral lymph nodes, re- 
activity was generally localized to the ablumenal aspect of 
the vessels (for example, see Fig.  1 c). On a serial section 
of this Peyer's patch, MECA-367,  an antibody raised against 
a  mucosal vascular addressin (Streeter  et al.,  1988),  in- 
tensely stains the full thickness of HEV in this tissue (Fig. 
1 d). While immunohistologic examination of the reactivity 
pattern for MECA-79 did not permit definition of the precise 
subcellular location of the antigen, the staining was consis- 
tent with  its presence  on the  ablumenal cell  membrane, 
and/or in association with the surrounding extracellular or 
cellular components  (e.g.,  basal  lamina or  pericytes).  A 
small subset of Peyer's patch HEV also bore low levels of cy- 
toplasmic and/or lumenal MECA-79 antigen. 
HEV in the intestine-draining mesenteric lymph node bind 
both  peripheral  lymph  node-specific  and  Peyer's  patch- 
specific HEV-binding lymphomas, suggesting the dual ex- 
pression of peripheral lymph node- and mucosa-associated 
endothelial cell determinants involved in lymphocyte recog- 
nition (Butcher et al., 1980). In keeping with these lympho- 
cyte-binding properties, we previously demonstrated that a 
mucosal vascular addressin is expressed by most HEV in this 
tissue  (Streeter  et  al.,  1988).  Immunohistologic staining 
with MECA-79 revealed that this marker is also present on 
mesenteric lymph node HEV. The pattern of staining ranged 
from intense full thickness reactivity comparable to that of 
peripheral lymph node HEV, to partial staining (Fig. 1 b) or, 
on rare venules, a complete lack of reactivity. Interestingly, 
the  staining intensity of positive  HEV  in  the  mesenteric 
lymph node was generally less than that of peripheral lymph 
node HEV. 
To assess directly the presence or absence of MECA-79 an- 
tigen at the lumenal surface of HEV and to facilitate a direct 
comparison between the expression of this antigen and the 
mucosal addressin (defined by MECA-367), MECA-79 and 
MECA-367  were  injected  intravenously  into  mice.  The 
recipients were sacrificed 15  min after injection and then 
gently perfused with 25 ml of HBSS over a 5-min period to 
remove unbound antibody from the vasculature. Perfusion 
was performed by injection of HBSS into the left ventricle 
of the heart, with perfusate removed from the venae cavae. 
Peyer's  patches,  mesenteric  lymph nodes,  and peripheral 
lymph nodes from these animals were then sectioned, and 
membrane-associated  MECA-79  (an  IgM  antibody)  and 
MECA-367  (IgG)  were  visualized by  immunoperoxidase 
staining of serial sections with anti-rat IgM or anti-rat IgG 
specific reagents. MECA-79 bound at high levels to periph- 
eral lymph node HEV (Fig. 2 a),  but was absent or only 
weakly detectable on the lumenal surface of most HEV in 
Peyer's  patches  (Figure 2  c).  Thus little of the MECA-79 
reactive antigen associated with Peyer's patch HEV is in di- 
rect contact with the blood. Interestingly, when perfusion 
was carried out under excessive pressure  (i.e.,  25  ml of 
HBSS  was  perfused  in  roughly  1.0-1.5 min),  MECA-79 
bound to the ablumenal aspect of Peyer's patch HEV, yield- 
ing much the same pattern as seen by direct immunohistol- 
ogy (except for the absence of cytoplasmic staining of HEC). 
Thus some or all of the ablumenal antigen is associated with 
extracellular components, pericytes, or the HEC membrane. 
In contrast to MECA-79, MECA-367 localized at high levels 
to Peyer's patch HEV (Fig. 2 f), but was not detectable on 
peripheral lymph node HEV (Fig.  2 d). 
Mesenteric lymph node HEV  in the animals receiving 
mAbs intravenously exhibited pronounced local variation in 
lumenal expression of both the MECA-367 and MECA-79 
defined  antigens.  While  most  HEV  in  this  gut-draining 
lymph node were stained with both antibodies (Figs. 2, b and 
e), a subset of HEV or portions of HEV stained exclusively 
with either MECA-367 or MECA-79. The exclusive expres- 
sion of one or the other of these antigens by HEV segments 
was confirmed by two-color immunofluorescence analysis 
(Figs. 3, a-d).  Cytoplasmic expression of the MECA-367 
and MECA-79 defined antigens by mesenteric lymph node 
high endothelial cells is explored further below.  No HEV 
staining was observed in recipients of control rat IgM or IgG 
antibodies. 
In the extralymphoid lamina propria of the small intestine, 
a mucosa-associated site that supports the extravasation of 
lymphocytes, all venules were MECA-79-,  whether assessed 
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sion of the MECA-79 antigen.  (a) 
Immunohistologic  staining  of pe- 
ripheral  lymph nodes  reveals that 
MECA-79 stains all HEV with in- 
tense cytoplasmic as well as appar- 
ent  lumenal  and  ablumenal  cell 
surface reactivity. (b) Most HEV in 
the  mesenteric  lymph  node  also 
stain  intensely  with  MECA-79. 
However, some HEV or portions of 
HEV  are  negative. (Arrow indi- 
cates  a  MECA-79- segment).  (c) 
In contrast,  in the mucosal Peyer's 
patches staining is generally local- 
ized to the ablumenal aspect of the 
venules. (Arrow  indicates a MECA- 
79  negative  segment.)  (d)  On  a 
serial  section of the Peyer's patch 
presented in c, the anti-mucosal ad- 
dressin  antibody, MECA-367, in- 
tensely stains the full thickness of 
all HEV. Bar, 50 ~tm. 
by direct immunohistology or in recipients of intravenously 
administered MECA-79.  Indeed,  immunohistologic exami- 
nation of a variety of normal extralymphoid tissues, includ- 
ing skin, skeletal muscle, mammary gland, and brain failed 
to reveal staining  with  MECA-79.  Table I  summarizes the 
results. 
MECA-79 Blocks Lymphocyte Binding to 
Peripheral Lymph Node HEV 
The tissue distribution  of the  MECA-79 antigen  suggested 
that it might function as a  specific recognition element in- 
volved  in  lymphocyte binding  to  peripheral  lymph  node 
HEV. We therefore asked whether MECA-79 could prevent 
lymphocyte binding  to  HEV  in  the  Stamper-Woodruff in 
vitro  assay.  Frozen  sections  of peripheral  lymph  nodes, 
mesenteric lymph nodes, and Peyer's patches were pretreated 
with a  saturating concentration of MECA-79,  an equivalent 
concentration of a control rat IgM antibody, or media alone, 
and  the  effect of pretreatment  on  the  binding  of normal 
mesenteric  lymph node  lymphocytes was determined.  As 
shown in Fig. 4, MECA-79 inhibited lymphocyte binding to 
peripheral lymph node HEV by 95 %. Consistent with the ex- 
pression  of both mucosal and  peripheral  lymph node  en- 
dothelial  cell  specificities  in  mesenteric  lymph  nodes, 
MECA-79 inhibited lymphocyte binding to HEV of this tis- 
sue by 54%. In contrast, lymphocyte binding to Peyer's patch 
HEV was not significantly effected.  Pretreatment of tissue 
sections with the control IgM antibody had no effect on lym- 
phocyte binding to the HEV of any tissue examined. A direct 
effect of MECA-79  on  the  lymphocytes was  ruled  out  by 
pretreatment of either the tissue sections or the lymphocytes 
followed  by  extensive  washing.  Under  these  conditions, 
The Journal of Cell Biology, Volume  107, 1988  1856 Figure 2. Analysis of the presence of the MECA-79 (a-c) and MECA-367 (d-f) antigens on the lumenal surface of HEV in peripheral 
lymph nodes (a and d) mesenteric lymph nodes (b and e) and Peyer's patches (c and  f). Briefly,  MECA-79  and MECA-367 were administered 
intravenously into mice. Recipients were sacrificed 15 min after injection and gently perfused with HBSS to remove unbound antibody 
from the vasculature. The lymphoid tissues of interest were then sectioned and membrane-associated MECA-79 and MECA-367 (IgM and 
IgG, respectively) were visualized by immunoperoxidase staining of serial sections with anti-rat IgM or anti-rat IgG specific reagents. 
MECA-79 was detected on the HEV of  peripheral lymph nodes (a) and mesenteric lymph nodes (b), but was absent or only barely detectable 
at the lumenal cell surface of most HEV in Peyer's patches (c). Thus most of the MECA-79 antigen detected by direct immunohistology 
on Peyer's patch HEV (Fig. 1 c) is associated with the ablumenal aspect of the HEV rather than the lumenal cell surface. In contrast to 
MECA-79, MECA-367 stained HEV in the Peyer's patches (f) and in mesenteric lymph nodes (e), but not in peripheral lymph node HEV 
(d). A, B, and C are serial sections of D, E, and F, respectively. Bar, 50 txm. 
pretreatment  of tissue  sections  yielded  results  similar  to 
those described above, while pretreatment of lymphocytes 
had no effect on binding. 
Most  normal  lymphocytes  appear  to  express  homing 
receptors for both peripheral lymph node and mucosal HEV 
(Butcher, E. C.,  1986; Stevens et al.,  1982). However, sub- 
sets of lymphocytes have been identified that bind to HEV 
in  a  highly  tissue  specific manner,  expressing  functional 
homing receptors for only a single HEV class (Butcher et al., 
1980;  Schmitz  et  al.,  1988).  To  determine  the  effect of 
MECA-79 on HEV binding by tissue-specific cells, we used 
two well-characterized lymphomas, TK1 and 38C13 (Butcher 
et al.,  1980;  Gallatin et al.,  1983).  MECA-79  effectively 
blocked the binding  of the  peripheral  lymph  node HEV- 
binding cell line, 38C13, to HEV in peripheral lymph nodes 
and mesenteric lymph nodes (Fig. 5). Conversely, MECA-79 
had no effect on binding of the mucosal HEV-specific cell 
line, TK1, to either Peyer's patch or mesenteric lymph node 
HEV. Binding of TK1 cells to mesenteric lymph node HEV 
occurred on most vessel segments, including those segments 
staining  intensely with  MECA-79  (assessed  immunohisto- 
logically in serial sections). MECA-79 therefore had no de- 
tectable effect on lymphocyte binding via mucosa-specific 
homing receptors, even when binding occurred to MECA- 
79  + HEV.  This excludes a  nonspecific inhibitory effect of 
MECA-79 on cell binding to positive vessels. These findings 
indicate that the MECA-79 antigen either mediates or associ- 
ates closely with endothelial cell elements mediating lym- 
phocyte  recognition  of  HEV  via  the  peripheral  lymph 
node-associated recognition system. 
MECA-79 Inhibits Lymphocyte Homing In Vivo 
Lymphocyte homing studies were used to assess the involve- 
ment of the MECA-79 antigen in tissue-specific lymphocyte 
extravasation under physiologic conditions in vivo. Normal 
mesenteric lymph  node cells  were labeled  with 5tCr  and 
transfused intravenously into mice that had previously re- 
ceived  i.v. injections  of either  MECA-79  or  an  isotype- 
matched control antibody. As predicted by our in vitro analy- 
ses, treatment with MECA-79 resulted in a substantial (64%) 
reduction in lymphocyte extravasation into peripheral lymph 
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the MECA-79 or MECA-367 anti- 
gens by some HEV segments  in 
the MLN, demonstrated  by two- 
color  immunofluorescence  his- 
tology. Two selected areas of mes- 
enteric  lymph  node  tissue  are 
shown,  one  (a  and  b)  illustrat- 
ing  HEV  segments  positive  for 
MECA-79 (a) but not for MECA- 
367 (b); the other (c and d) dem- 
onstrating  HEC  staining  with 
MECA-367 (d) but not MECA-79 
(c). The arrows identify reference 
cells or HEV segments within the 
sections that stain with both anti- 
bodies.  Bar, 50 I.tm. 
nodes, a partial (35 %) blockade in lymphocyte localization 
to mesenteric lymph nodes, and no significant effect on hom- 
ing to Peyer's patches  (Fig.  6). 
The tissue-selective expression of the MECA-79 antigen in 
combination  with  its  functional  involvement  in  tissue- 
specific lymphocyte HEV interactions  both in vitro and in 
vivo  qualify  it  as  a  "vascular  addressin"  (Streeter  et  al., 
1988). 
Table L Tissue-specific Distribution of  the MECA-79 
Antigen (Peripheral Lymph Node Addressin) and the 
MECA-367 Antigen (Mucosal Addressin) 
Relative staining intensity with mAb 
Tissue  MECA-79  MECA-367 
Peripheral lymph nodes  + + +  - 
Mesenteric lymph nodes  + + -- + + +*  + + -- + + + * 
Peyer's patches  + ~  + + + 
Lamina propria of the gut  -  + + § 
Lactating mammary gland  -  + + § 
Normal skin  -  - 
Skeletal muscle  -  - 
Brain  -  - 
MECA-79 and MECA-367 exhibit distinct distributions in lymphoid and ex- 
tralymphoid tissues. The staining intensity in the different tissues ranges from 
undetectable levels (-)to  high levels (+ + +). 
* In the mesenteric lymph node,  some HEV or HEV  segments are negative. 
~t Staining of Peyer's patch HEV with MECA-79 is generally restricted to the 
ablumenal aspect of HEC.  Some vessels express barely detectable levels of 
MECA-79 on their lumenal cell surface. 
§ MECA-367 stains small vessels in both the lamina propria of the gut and the 
lactating mammary gland.  These  small vessels are  morphologically distinct 
from the HEV that stain in organized lymphoid tissues. 
Individual HEC Can Express Both Peripheral 
Lymph Node and Mucosal Addressins Simultaneously 
We next asked whether expression of peripheral lymph node 
and mucosal addressins by HEC in mesenteric lymph nodes 
was mutually exclusive, or whether both addressins could be 
coexpressed by individual cells. Immunohistologic examina- 
tion  of mesenteric  lymph  node  serial  sections,  described 
above, had suggested that both the mucosal addressin  (de- 
fined by MECA-367) and the peripheral lymph node addressin 
(the  MECA-79 antigen)  might be coexpressed  cytoplasmi- 
cally by HEC in this tissue. Our two-color immunohistologic 
staining of tissues from animals that received mAbs intrave- 
nously  (described  above),  suggested  that  individual  HEC 
could also express both addressins at the cell surface simul- 
taneously.  To examine these questions further,  a  single-cell 
suspension  of  enzyme-dispersed  mesenteric  lymph  node 
HECs was prepared,  and endothelial  cells  (either  acetone 
fixed cytospins or viable cells  in suspension)  were stained 
with MECA-367 and MECA-79 (or either antibody alone vs. 
control antibodies, as described in Materials and Methods). 
In keeping  with  the  direct  immunohistology and  the  two- 
color staining of perfused tissues,  the mucosal and periph- 
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Figure 4. MECA-79 selectively inhibits the in vitro binding of lym- 
phocytes to peripheral  lymph node HEV. MECA-79 blocks the 
binding of normal lymphocytes to mesenteric lymph node and pe- 
ripheral lymph node HEV, without significantly influencing lym- 
phocyte binding to mucosal (Peyer's patch) HEV. The partial reduc- 
tion  in lymphocyte binding to mesenteric lymph node HEV  is 
consistent with their expression of both peripheral lymph node and 
mucosal addressins. The isotype matched control antibody, 2C2, 
has no effect on lymphocyte binding. PLN, peripheral lymph node; 
MLN, mesenteric lymph node; and PP, Peyer's patches. Results are 
presented as percent of media control (+SEM). 
eral lymph node addressins appeared to  be present on both 
the cell surface and  in the cytoplasm of most mesenteric 
lymph node HEC, and as predicted above, a small fraction 
of cells stained exclusively with either MECA-79 or MECA- 
367. The results are summarized in Table II. Isotype-matched 
control antibodies were negative. 
Discussion 
We have described a mAb, MECA-79,  that recognizes an an- 
tigen that is selectively expressed on the lumenal cell surface 
of vessels associated with lymphocyte extravasation into pe- 
ripheral lymph nodes and that appears to be required for 
adhesion of normal and neoplastic lymphocytes to the HEV 
Table II. Cell Surface and Cytoplasmic Expression of 
Addressins by Enzyme-dispersed Mesenteric Lymph Node 
High Endothelial Cells 
Percentage  of HEC bearing 
peripheral lymph node and/or 
mucosal  addressin 
Addressin expressed  Cell surface  Cytoplasmic 
Peripheral lymph node only 
(MECA-79÷; MECA-367-)  17  7 
Mucosal only 
(MECA-79-; MECA-367  ÷)  10  6 
Both 
(MECA-79+; MECA-367  ÷)  73  87 
Immunohistologic  examination of mesenteric lymph node  serial sections  sug- 
gested that the  peripheral lymph node  addressin and  the mucosal addressin 
might be coexpressed by HEC in this tissue.  To address this possibility, we 
used two-color immunofluorescence  analysis to assess expression of these ad- 
dressins both on the cell surface and within the cytoplasm of enzyme-dispersed 
mesenteric lymph node HEC (see Materials and Methods for details). While 
most of the isolated HEC appeared to express both peripheral lymph node and 
mucosal addressins on the cell surface as well as cytoplasmically,  a small sub- 
set of cells exclusively  express either the peripheral lymph node or the mucosal 
addressin. 
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Figure 5.  MECA-79 selectively inhibits peripheral  lymph node- 
homing receptor-mediated lymphoma binding to HEV. MECA-79 
blocks the binding of a peripheral lymph node-specific lymphoma 
(38C13) to peripheral  lymph node and  mesenteric lymph node 
HEV, but has no effect on the binding of TK1, a lymphoma that 
binds to HEV in mesenteric lymph nodes and Peyer's patches via 
mucosal-homing receptors. Cell binding was not influenced by the 
class-matched control antibody, 2C2. Results are presented as per- 
cent of media control (+SEM). 
of these lymphoid organs./VlECA-79 inhibits the binding of 
normal lymphocytes to peripheral lymph node HEV, and has 
no  significant  effect on  lymphocyte binding  to  HEV  in 
mucosa-associated  lymphoid  organs,  the  Peyer's patches. 
MECA-79 blocks 38C13,  a  lymphoma that selectively ex- 
presses  peripheral  lymph  node-homing  receptors,  from 
binding to peripheral lymph node or to mesenteric lymph 
node HEV. In contrast, the antibody has no effect  on the abil- 
ity of TK1, a mucosal HEV-specific lymphoma, to bind to 
HEV in Peyer's patches or in mesenteric lymph nodes even 
when  the  HEV  bound  are  MECA-79  +,  thus  ruling  out a 
nonspecific effect of the antibody on cell adhesion to MECA- 
79  + HEV. Finally, the i.v. administration of MECA-79 dra- 
matically reduces the extravasation of normal blood-borne 
lymphocytes into peripheral lymph nodes in vivo. These data 
indicate that the antigen defined by MECA-79 is involved in 
the tissue-selective recognition of HEV by normal lympho- 
cytes and transformed lymphoid cells, and is required for the 
homing of normal lymphocytes to peripheral lymph nodes in 
vivo.  This  vascular  addressin  must  either  function  as  a 
specific endothelial cell surface ligand for peripheral lymph 
node-homing receptors or be associated both physically and 
functionally with such a ligand. Proof of its role in lympho- 
cyte  interactions  with  endothelium  will  require  molecu- 
lar characterization, including the demonstration that as an 
isolated molecule it is  capable of binding either lympho- 
cytes  or  lymphocyte homing  receptors  with  appropriate 
specificity. 
A particularly interesting aspect of the expression of the 
MECA-79 antigen is that, although it is either absent or pres- 
ent at only low levels on the lumenal surface of most HEV 
in  Peyer's patches,  it is  nonetheless  expressed at the  ab- 
lumenal aspect of many vessels in this site.  While the level 
of resolution obtained in the current study does not permit 
definitive identification of the subcellular position of the ad- 
Streeter  et al. A Peripheral Lymph Node  Vascular Addressin  1859 Figure 6. Inhibition of  lymphocyte homing by MECA-79. MECA-79 
was administered intravenously. 4 h later 5~Cr-labeled mesenteric 
lymph  node  cells  were  injected  intravenously and  2  h  later, 
recipients were sacrificed.  Cell  localization was  determined by 
quantitating the cpm in the indicated tissues. Relative localization 
in MECA-79-treated recipients is expressed as a percent of that ob- 
served in recipients of an isotype-matched control antibody, OZ-42 
(+SEM), and represents data pooled from two experiments with 
similar results. Three to four animals were included in each treat- 
ment group in these experiments. Lung tissue was harvested in only 
one of the two experiments. Intravenous injection of MECA-79 
resulted in a substantial reduction in lymphocyte homing to periph- 
eral lymph nodes, a partial reduction in lymphocyte extravasation 
into mesenteric lymph nodes and had no significant effect on hom- 
ing to Peyer's patches. 
dressin, the antigen could be present in either the ablumenal 
plasma membrane of HEC, or in association with pericytes 
and  the  surrounding  extracellular  material.  This  finding 
raises the possibility that the tissue-selective function of this 
molecule in  lymphocyte trafficking may be  regulated  not 
only at the level of synthesis and expression,  but also by 
selective control of translocation  to  the  (lumenal  vs.  ab- 
lumenal) cell surface. Alternatively, localization to the lu- 
menal surface may be determined by specific adhesive inter- 
actions with other endothelial cell products, perhaps residing 
in the carbohydrate-rich glycocalyx that is a prominent fea- 
ture of HEC and that may be the initial point of lympho- 
cyte-HEC contact (Anderson and Anderson,  1976). 
The pattern of expression of the MECA-79-defined ad- 
dressin contrasts with that of  the mucosal vascular addressin, 
defined by mAb MECA-367, which is expressed at high lev- 
els on Peyer's patch HEV and is essentially absent from HEV 
in peripheral lymph nodes. The mucosal vascular addressin 
has been identified as a  protein with a  molecular mass of 
58-66 kD. Use of MECA-79 to isolate the peripheral lymph 
node addressin for biochemical characterization has proven 
difficult, perhaps implying a  relatively low affinity of this 
IgM antibody for its antigen. 
The mesenteric lymph node, which receives its lymphatic 
drainage from the intestines, is unique among lymph nodes 
examined in that it contains HEV that express moderate lev- 
els of both peripheral and mucosal addressins.  The present 
studies demonstrate that, although some mesenteric lymph 
node HEC bear only the antigens defined by MECA-79  or 
MECA-367, most express intracellular and cell surface ad- 
dressins of both peripheral lymph node and mucosal types. 
External factors, perhaps arriving via lymph, may provide 
information regarding the position or tissue association of 
lymphoid tissues, and act on HEC to regulate addressin ex- 
pression. The simultaneous expression of peripheral lymph 
node and mucosal addressins by individual endothelial cells 
within  the  mesenteric  lymph  node  suggests  that  the  en- 
dothelial cell response to such signals is not.all or none. In- 
stead, each of the addressins may be independently induced 
and regulated. The exclusive expression of either mucosal or 
peripheral lymph node addressin by a subset of HEC in the 
mesenteric lymph node, and indeed by whole HEV or large 
segments of HEV, may imply either differential responsive- 
ness of HEC clones to mucosal (or peripheral lymph node) 
addressin-inducing factors or differential exposure of HEV 
segments to such factors. 
In addition to tissue-specific signals,  immune response- 
associated factors are also likely to be involved in regulating 
the expression of vascular addressins and other features of 
high  endothelial  cell  differentiation.  Hendriks  and  Ester- 
mans (1983)  demonstrated that surgical interruption of the 
afferent lymph supply into rat peripheral lymph nodes causes 
HEV to lose their high-walled phenotype, appearing as fiat- 
walled, nonfunctional vessels after two to three weeks. The 
characteristic high-walled phenotype was reinduced after the 
injection of antigen directly into the lymph node, suggesting 
that specific factors regulating HEC differentiation may be 
elaborated during immune responses. Indeed, it is likely that 
conventional cytokines play a role in inducing or maintaining 
the HEC phenotype. We have shown that a marker of high 
endothelial cell differentiation is induced on cultured capil- 
lary endothelial cells after treatment with interferon-gamma 
(Duijvestijn et al.,  1986). Cytokines have also been shown 
to influence the adhesiveness of cultured endothelial cells for 
leukocytes (Bevilacqua et al., 1985; Cavender et al., 1986). 
These considerations suggest that the HEC phenotype, prob- 
ably including expression of particular addressins, is deter- 
mined by local environmental influences acting on maleable 
endothelial cells in the adult. It remains formally possible, 
however, that the specificity of the addressin expressed is de- 
termined by tissue-specific influences on endothelial cells 
during  fetal development,  and  that  these  specificities are 
maintained in the adult. 
Tissue-specific endothelial  cell  differentiation has  been 
reported in other systems, as well. For example, Auerbach 
et al.  (1987)  and Alby and Auerbach (1984) presented evi- 
dence that the adhesive capacity of certain tumor cells for 
capillary endothelial cells from different sites correlates with 
their organ-selective metastatic patterns. Similarly, Nicolson 
et al.,  (1988)  found that liver- vs.  lung-colonizing sublines 
of the  lymphosarcoma RAWll7  preferentially bind  endo- 
thelial cell monolayers derived from liver or lung,  respec- 
tively. Risau et al. (1986) recently described a tissue-specific 
molecule that is found selectively on brain endothelium in 
the mouse, and demonstrated that its induction in embryonic 
tissue correlates with  the development of the blood-brain 
barrier.  Local  cellular  or  microenvironmental  influences 
also appear to be critically important in at least some exam- 
pies of tissue-specific endothelial cell differentiation. For ex- 
ample, Janzer and Raft (1987)  dramatically illustrated that 
astrocytes injected into the cornea induce local vessels to ex- 
press a  diffusion barrier similar to that of the blood/brain 
barrier. 
Stoolman et al. (1984), Rosen et al.  (1985), and Yednock et 
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face carbohydrate components may play an important role in 
lymphocyte  recognition  of peripheral  lymph  node  HEV. 
They found that both mannose-6-phosphate (Stoolman et al., 
1984)  and  the mannose-6-phosphate-rich  phosphomannan 
ester core structure  (PPME)  from Hansenula holstii (Yed- 
nock et al., 1987b) block the binding of lymphocytes to both 
rat and mouse peripheral lymph node HEV.  Furthermore, 
PPME binds to peripheral lymph node HEV-binding  lym- 
phocytes or lymphoid cell lines, and this interaction  is spe- 
cifically inhibited by the anti-peripheral  lymph node-homing 
receptor mAb, MEL-14 (Yednock et al., 1987a), suggesting 
that the peripheral lymph node-homing  receptor functions 
as a mammalian  lectin in binding tissue-specific  carbohy- 
drate (or carbohydrate-protein combined) determinant(s)  on 
HEV. This interpretation is supported further by the observa- 
tion that sialidase treatment  inhibits  lymphocyte binding to 
peripheral  lymph node but not to mucosal HEV (Rosen et 
al.,  1985).  Thus, it will be important to examine the contri- 
bution of carbohydrate  to the structure  and function of the 
vascular  addressins we have defined. 
Our findings  confirm the  existence of two antigenically 
distinct  and  independently  regulated  vascular  addressins, 
one supporting  lymphocyte extravasation  into mucosal lym- 
phoid tissues (Streeter  et al.,  1988),  and the other into pe- 
ripheral  lymph  nodes.  The existence  of these  two tissue- 
specific endothelial cell molecules has been postulated  for 
several years, based not only on the tissue-selective homing 
properties of distinct lymphocyte subsets, but also on tissue- 
selective  inhibitory  effects  of  mAbs  against  lymphocyte 
"homing receptors" (Gallatin  et al., 1983;  Rasmussen et al., 
1985;  Chin et al.,  1986; Jalkanen et al.,  1987).  Functional 
studies have implied the existence of at least one additional 
vascular addressin involved in lymphocyte homing to inflamed 
joints  (Jalkanen  et al.,  1986b).  Antigenic  identification of 
this inflammation- or joint-specific endothelial cell addres- 
sin, and additional  addressins that may be expressed in other 
tissues will be an important area for further investigation. In 
light of evidence that lymphocyte homing receptors of differ- 
ent specificities are closely related  (Jalkanen et al.,  1987), 
it is possible that endothelial cell antigens involved in lym- 
phocyte-endothelial  cell interactions  will also prove  to be 
very similar, perhaps representing a family of evolutionarily 
and  structurally  related  molecules defining the position or 
tissue association of vessels throughout  the body. 
In conclusion,  we have  described the immunohistologic 
identification and  tissue distribution  of an endothelial cell 
differentiation  antigen involved in lymphocyte recognition of 
peripheral lymph node HEV in the mouse. Examination of 
the nature and regulation of this peripheral lymph node ad- 
dressin,  and  the  mucosal  addressin  described  previously 
(Streeter  et al.,  1988),  should not only enhance our under- 
standing  of the  mechanisms  controlling  lymphocyte  entry 
into diverse tissues, but may also provide insight into the mo- 
lecular and cellular processes directing cell-cell interactions 
and cellular positioning in other systems. 
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